GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Shiller PE Ratio

MorphoSys AG (XSWX:MOR) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


MorphoSys AG Shiller PE Ratio Historical Data

The historical data trend for MorphoSys AG's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Shiller PE Ratio Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MorphoSys AG's Shiller PE Ratio

For the Biotechnology subindustry, MorphoSys AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Shiller PE Ratio falls into.



MorphoSys AG Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MorphoSys AG's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, MorphoSys AG's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/123.7729*123.7729
=0.000

Current CPI (Dec. 2023) = 123.7729.

MorphoSys AG Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.049 99.543 0.061
201406 -0.024 99.543 -0.030
201409 -0.121 99.823 -0.150
201412 -0.048 99.543 -0.060
201503 1.644 99.717 2.041
201506 -0.178 100.417 -0.219
201509 -0.349 100.417 -0.430
201512 -0.564 99.717 -0.700
201603 -0.306 100.017 -0.379
201606 -0.490 100.717 -0.602
201609 -0.535 101.017 -0.656
201612 -1.151 101.217 -1.407
201703 -0.557 101.417 -0.680
201706 -0.609 102.117 -0.738
201709 -0.952 102.717 -1.147
201712 -0.584 102.617 -0.704
201803 -0.783 102.917 -0.942
201806 -0.879 104.017 -1.046
201809 1.073 104.718 1.268
201812 -1.557 104.217 -1.849
201903 -0.814 104.217 -0.967
201906 -0.212 105.718 -0.248
201909 -0.829 106.018 -0.968
201912 -1.736 105.818 -2.031
202003 6.477 105.718 7.583
202006 -1.739 106.618 -2.019
202009 -2.155 105.818 -2.521
202012 -0.584 105.518 -0.685
202103 -1.406 107.518 -1.619
202106 0.667 108.486 0.761
202109 -3.583 109.435 -4.052
202112 -11.614 110.384 -13.023
202203 -3.675 113.968 -3.991
202206 -7.056 115.760 -7.544
202209 -3.469 118.818 -3.614
202212 0.000 119.345 0.000
202303 0.000 122.402 0.000
202306 0.000 123.140 0.000
202309 0.000 124.195 0.000
202312 0.000 123.773 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MorphoSys AG  (XSWX:MOR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MorphoSys AG Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (XSWX:MOR) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.